Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Point State Capital Boosts its Stake in The Medicines Company (MDCO) to 7%

Led by Sean CullinanPoint State Capital revealed a significantly increased position in The Medicines Company (NASDAQ:MDCO). The updated position amounts to almost 4.70 million shares, which represent a 7.30% passive stake in the company’s common stock. Previously, Point State owned 900,000 shares in The Medicines..

The Medicines Company (NASDAQ:MDCO)

Founded in 1996 and employing approximately 425 professionals, The Medicines Company (NASDAQ:MDCO) is a global pharmaceutical company focused on advancing the treatment of critical care patients by supplying the hospital marketplace with three main innovative and cost-effective medicines: Angiomax, Cleviprex, and Argatroban Injection. The company also has several other hospital products under development. In a recent press release, The Medicines Company announced that the U.S. Food and Drug Administration (FDA) accepted the filing of a biologic license application for Fibrocaps hemostatic agent  – a dry powder formulation developed to aid in hemostasis during surgery. In 2013, the company generated net profits of $15.50 million – an equivalent of $0.27 per share. On average, analysts strongly suggest that investors buy the stock, estimating that  The Medicines would produce earnings per share of $1.68 and $2.66 in 2014 and 2015, respectively.

Other significant shareholders of The Medicines Company (NASDAQ:MDCO) include Christopher Medlock‘s Partner Fund Management, which holds 2.10 million shares with an aggregate value of $81.70 million. Royce & Associates, a fund managed by Chuck Royce, owns a $177.00 million worth position of 4.60 million shares in the company.

Having a market value of nearly $8.00 billion, Point State Capital’s equity portfolio is 40.00% invested in the Services Sector.
Cheniere Energy, Inc. (NYSEMKT:LNG) represents a 6.55% stake in the portfolio, the position amassing more than 12.00 shares worth almost $520.00 million. The fund also holds significant positions in Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Walgreen Company (NYSE:WAG), with 9.45 million shares worth $378.60 million in the former and 6.12 million shares worth $351.80 million in the latter.

Disclosure: None

Recommended Reading:

Jeffrey Smith, Starboard Value’s Investor Presentation On Darden Restaurants, Inc.(DRI); Argue Against Red Lobster Spin-off

Kevin Kotler’s Broadfin Capital’s and MELA Sciences (MELA)

Jeffrey Tannenbaum Slightly Increases Holding of CIG Wireless Corp (CIGW)

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!